Your browser doesn't support javascript.
loading
Comparative effectiveness of second-line ipilimumab vs. nivolumab in combination with ipilimumab in patients with advanced melanoma who received frontline anti-PD-1 antibodies.
Baron, Kelsey; Moser, Justin C; Patel, Shiven; Grossmann, Kenneth F; Colonna, Sarah V; Hyngstrom, John R.
  • Baron K; Department of Internal Medicine, Intermountain Medical Center, Murray, USA.
  • Moser JC; HonorHealth Research Institute, Scottsdale, USA.
  • Patel S; Division of Medical Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, USA.
  • Grossmann KF; Division of Medical Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, USA.
  • Colonna SV; Division of Medical Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, USA.
  • Hyngstrom JR; Division of Surgical Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, USA.
J Oncol Pharm Pract ; 27(3): 555-559, 2021 Apr.
Article en En | MEDLINE | ID: mdl-32423325
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Receptor de Muerte Celular Programada 1 / Ipilimumab / Nivolumab / Inmunoterapia / Melanoma Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Receptor de Muerte Celular Programada 1 / Ipilimumab / Nivolumab / Inmunoterapia / Melanoma Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Año: 2021 Tipo del documento: Article